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Background: Enhancer of zeste homolog 2 (EZH2), a member of the polycomb group proteins, has been shown to
promote cancer progression and breast cancer stem cell (CSC) expansion. Breast CSCs are associated with resistance
to radiation in inflammatory breast cancer (IBC), a rare but aggressive variant of breast cancer. In this retrospective
study, we examined the clinical role of EZH2 in locoregional recurrence (LRR) of IBC patients treated with radiation.
Patients and methods: 62 IBC patients who received radiation (7 pre-operative, 55 post-operative) and had
adequate follow up to assess LRR were the subject of this study. Positive EZH2 status was defined as nuclear
immunohistochemical staining in at least 10% of invasive cancer cells. Association of EZH2 expression with
clinicopathologic features were evaluated using the Chi-square statistic and actuarial LRR free survival (LRFS) was
determined using the Kaplan-Meier method.
Results: The median follow-up for this cohort was 33.7 months, and the 5-year overall LRFS rate was 69%. Of the
62 patients, 16 (25.8%) had LRR, and 15 out of 16 LRR occurred in EZH2 expressing cases. Univariate analysis
indicated that patients who had EZH2-positive IBC had a significantly lower 5-year locoregional free survival (LRFS)
rate than patients who had EZH2-negative IBC (93.3% vs. 59.1%; P = 0.01). Positive EZH2 expression was associated
significantly with negative ER status (97.1% in ER- vs 48.1% in ER+; P < 0.0001) and triple-negative receptor status
(P = 0.0001) and all triple-negative tumors were EZH2-positive. In multivariate analysis, only triple negative status
remained an independent predictor of worse LRFS (hazard ratio 5.64, 95% CI 2.19 – 14.49, P < 0.0001).
Conclusions: EZH2 correlates with locoregional recurrence in IBC patients who received radiation treatment. EZH2
expression status may be used in addition to receptor status to identify a subset of patients with IBC who recur
locally in spite of radiation and may benefit from enrollment in clinical trials testing radiosensitizers.
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The use of ionizing radiation is an integral component
of breast cancer treatment for all patients who receive
breast conserving surgery and in most patients with lo-
cally advanced breast cancer. Resistance to radiation is,
however, a common reason for local recurrence in breast
cancer patients, especially in breast cancers with high* Correspondence: wwoodward@mdanderson.org
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unless otherwise stated.risk of recurrence such as inflammatory and triple-
negative breast cancers [1,2]. Recurrence is thought to be
driven in part by tumor initiating cells or cancer stem cells
(CSCs), a subpopulation of self-renewing cancer cells
which exhibit tumor initiating properties and have been
shown to contribute to the development of resistance to
radiation and chemotherapy. Our lab and others have pro-
vided evidence that breast CSCs are resistant to radiation
[3–5] although detailed mechanisms of resistance have yet
to be fully investigated.
Inflammatory breast cancer (IBC) is a rare but aggres-
sive variant of invasive breast cancer characterized byLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Debeb et al. Journal of Experimental & Clinical Cancer Research 2014, 33:58 Page 2 of 7
http://www.jeccr.com/content/33/1/58rapid progression, enlargement of the breast, skin edema
and erythema. Typically, IBC is associated with rapid me-
tastasis, resistance to treatment, and poor prognosis–all
hallmarks of the CSC hypothesis. To date clinical and pre-
clinical data strongly correlate CSCs with IBC [6]. Despite
advances in multimodal breast cancer care, the clinical
outcome of these patients remains poor demonstrating a
critical need to identify novel therapeutics that target the
distinct biology of IBC. A recent study by Gong and col-
leagues [7] showed that Enhancer of zeste homolog 2
(EZH2), a member of the polycomb group proteins, is
expressed very frequently in IBC and is associated with
worse clinical outcome in these patients. This work was
supported by in vitro findings that EZH2 is expressed at
higher levels in human IBC cell lines and its knockdown
suppresses growth and invasion in IBC cells [8]. Previous
studies have shown that EZH2 is involved in maintaining
the self-renewal capability of adult and embryonic stem
cells [9,10] and recently, Chang et al has demonstrated
that EZH2 promotes the expansion of breast CSCs and
that it impairs DNA repair in breast cancer cells by spe-
cific downregulation of RAD51 gene [11]. In addition, they
showed that HIF1α, a known mediator of radiation resist-
ance, transactivated the EZH2 gene and increased EZH2
expression under hypoxic conditions [11]. These findings
suggest a possible involvement of EZH2 in radioresistance,
however, the clinical role of EZH2 in local failure and radi-
ation resistance in breast cancer patients is unknown.
Herein, we investigated the relation between EZH2 ex-
pression and locoregional failure and found that positive
EZH2 expression correlates with lower locoregional recur-
rence free survival after radiation in IBC patients.Materials and methods
This study was approved by The University of Texas MD
Anderson Cancer Center Institutional Review Board. TheFigure 1 Representative images for immunohistochemical staining of
(B) EZH2-positive IBC tumor.diagnosis, preoperative and postoperative treatments of
these patients, biomarker study (encompassing ER, PR,
and HER2 status), and tissue microarray (TMA) construc-
tion using post-neoadjuvant residual tumors as well as
EZH2 immunohistochemical staining and evaluation were
previously reported [7]. EZH2 staining was interpreted
and recorded independently by 2 pathologists (Y.G. and
L.H.) in a blinded manner. Positive EZH2 status was de-
fined as nuclear staining in at least 10% of invasive can-
cer cells. Images of negative and positive EZH2 staining
results in representative tumors are shown in Figure 1.
To evaluate the role of EZH2 in radiation resistance, the
radiation record of all patients was re-reviewed and only
patients who received radiation (62 patients) were in-
cluded in this study. Patients who had local failure prior
to receiving radiation were excluded from this analysis.
Statistical analysis
Chi-square or Fisher exact test was used to evaluate as-
sociations between EZH2 status and clinicopathologic var-
iables. We used the Kaplan-Meier method to estimate
actuarial LRR free survival (LRFS). LRFS was calculated
from the date of initial pathologic diagnosis of the primary
tumor to the date of locoregional recurrence or the date
of last follow-up and any locoregional recurrence was con-
sidered an event. A Cox proportional hazards regression
model was then used to test the statistical significance of
several potential prognostic factors for LRFS. The fac-
tors analyzed included EZH2 expression; age; race;
lymph node status; histologic type; lymphovascular in-
vasion; ER, PR, and HER-2 status; triple-negative (ER-
negative, PR-negative, and HER2 negative) status; and
twice-a-day (BID) radiation. This modeling was done in
a univariate fashion. Then, all potential prognostic fac-
tors with a P value < .25 from the univariate analysis
were included in a saturated model, and backward elimin-
ation was used to remove factors from the model basedEZH2 in IBC tumors (A) EZH2-negative IBC tumor
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lysis. All statistical analysis was conducted using Stata-
Corp. 2011. Stata Statistical Software: Release 12. College
Station, TX: StataCorp LP. All reported P values were 2-
sided, and P < 0.05 was considered statistically significant.
Results
The cohort of IBC patients used in this study and the
EZH2 expression were described previously [7]. Briefly,Table 1 Comparison of clinicopathological parameters in wom
Prognostic factors EZH2 negative
Number of patients Percent
Age of diagnosis (N = 62)
≥ 45 11 68.75
< 45 5 31.25
Race (N = 59)
Non-Hispanic White 15 93.75
All others 1 6.25
Lymph node status (N = 60)
Negative 3 18.75
Positive 13 81.25
Histologic type (N = 62)
Ductal 12 75.0
Others 4 25.0
Lymphovascular invasion (N = 56)
No 4 26.67
Yes 11 73.33
ER expression (N = 61)
Negative 1 6.67
Positive 14 93.33
PR expression (N = 61)
Negative 8 53.33
Positive 7 46.67
HER2 expression (N = 61)
Negative 11 73.33
Positive 4 26.67
Triple-negative status (N = 61)
No 15 100.00
Yes 0 0.00
Radiation type (N = 62)
Preoperative 1 6.25
Postoperative 15 93.75
BID radiation (N = 48)
No 0 0.00
Yes 10 100.00
Radiation dose (N = 48) Dose
11 67.09tumors from 88 patients with primary IBC were in-
cluded of which EZH2 staining was available for 74 tu-
mors. Patients received multimodal treatment, including
neoadjuvant chemotherapy, surgery, and radiation ther-
apy. At the completion of neoadjuvant chemotherapy, all
patients underwent mastectomy; most patients also under-
went axillary lymph node dissection. Thirty-one patients
received adjuvant endocrine therapy, and all patients with
HER2-positive tumors received adjuvant trastuzumab.en who received radiation stratified by EZH2 expression
EZH2 positive
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Seven patients previously classified as post-op radiation
[7] were noted to have had pre-operative radiation. In total,
sixty-two patients received radiation (7 pre-operative, 55
post-operative) to the chest wall and draining lymphatics.
In this study, we reviewed the radiation record of these pa-
tients to evaluate the role that EZH2 plays in mediating ra-
diation resistance in clinically radioresistant IBC.
In the 62 patients who received radiation, the median
follow-up was 33.7 months (range, 1.1-181.5 months). The
age at the time of initial diagnosis ranged from 23 years to
75 years (median age, 48 years). Forty-eight (81.3%) were
whites, 8 (13.5%) were Hispanics, and 3 (5.1%) were Blacks
and Asians. Lymph node involvement was observed in 53
of 60 patients (88.3%). Histologically, 54 of 62 tumors
(87.1%) were ductal type, and 47 of 56 (83.9%) demon-
strated lymphovascular invasion. Positive ER expression
was observed in 27 of 61 of tumors (44.2%), positive PR
status was observed in 19 of 61 tumors (31.1%), and HER2
overexpression and/or amplification was observed in 22 of
61 tumors (36.1%). Triple-negative status was observed in
16 of 61 tumors (26.2%). Thirty-eight of 48 (79.2%) IBC
patients received BID radiation, of which 37 (77.1%) re-
ceived a total dose of 63.47 Gy and the remaining received
a dose of 67.09 Gy.EZH2 expression and clinicopathologic variables in
patients who received radiation
In this cohort positive EZH2 expression was associated sig-
nificantly with negative ER status (P < 0.0001) and triple-
negative status (P = 0.005). Specifically EZH2 was expressed
more frequently in ER-negative (97.1%; 33 of 34 ER- tu-
mors) than ER-positive patients (48.1%; 13 of 27 ER + tu-
mors) treated with radiation (Table 1). All triple-negative
tumors were EZH2-positive. EZH2 expression was not as-
sociated significantly with lymphnode status, histologic
type, lymphovascular invasion, PR status, HER2 status and
BID radiation (Table 1). Similar results were found whenFigure 2 Kaplan Meier curve showing that EZH2 is associated with lo
post-operative radiation treatment (N = 62) and B) Postmastectomy radiatio
significantly higher than in EZH2-positive cases (P = 0.01).only post mastectomy radiation-treated IBC patients were
analyzed (data not shown).EZH2 expression and local failure
Of the 62 patients who had follow-up information avail-
able on LRR, the median LRFS duration was 4.04 years
(95% CI, 2.85-8.79 years). The 5-year LRFS rate for the
entire cohort of patients was 69% (Figure 2). Sixteen
(25.8%) had LRR and notably 15 of the 16 LRR occurred
in EZH2 positive patients. In univariate analysis, positive
EZH2 expression was associated significantly with a
lower LRFS rate (P = 0.01) (Figure 2). The 5-year LRFS
rate for patients who had EZH2-positive tumors was
59.1% compared with 93.3% for patients who had EZH2-
negative tumors (Figure 2A). Among the 55 patients
who had post mastectomy radiation, positive EZH2 ex-
pression was also significantly associated with lower
LRFS rates (5-year LRFS EZH2-positive = 59.4%, EZH2-
negative = 92.9%, P = 0.01; Figure 2B).
Univariate analyses were performed to determine
whether any other clinicopathologic factors were associ-
ated with the clinical outcome of IBC patients. We ob-
served that lower LRFS rates were associated significantly
with negative ER status (P = 0.001) and with triple-
negative status (Table 2; P = 0.0001). There was no signifi-
cant association between LRFS rates and histologic type,
age, race, lymph node status, and HER2 status while there
was a trend with lymphovascular invasion (P = 0.07). In
multivariate analysis, we observed that only triple negative
status remained an independent predictor of LRFS (hazard
ratio 5.64, 95% CI 2.19 – 14.49, P < 0.0001; Table 3). We
reasoned that failure of EZH2 to predict local recurrence
was influenced by triple negative-receptor-status since all
of the triple-negative tumors were EZH2-positive. Thus,
we excluded triple negative tumors from the analysis and
we found that EZH2 has a trend to be an independent
predictor of worst LRFS in the 45 IBC patients analyzed
(6.57, 95% CI 0.82-52.87; P = 0.08) (Table 4).wer LRFS in IBC patients. A) All patients who received pre- and
n cohort (N = 55) showed that the LRFS in EZH2 negative cases was
Table 2 Relation between LRFS, EZH2 and clinicopathologic factors in patients who received radiation
Prognostic factors Number of patients/number of deaths 5-year LRFS (95% CI) P value
Age of diagnosis (N = 62)
≥ 45 40/12 72.7 (54.8 – 84.8) 0.43
< 45 22/7 60.9 (33.9 – 79.6)
Race (N = 59)
Non-Hispanic White 48/13 74.3 (58.4 – 85.1) 0.36
All others 11/4 56.1 (19.5 – 81.5)
Lymph node status (N = 60)
Negative 7/2 83.3 (27.3 – 97.4) 0.79
Positive 53/16 67.3 (51.3 – 79.2)
Histologic type (N = 62)
Ductal 54/17 68.7 (53.2 – 80.1) 0.72
Others 8/2 75.0 (31.5 – 93.1)
Lymphovascular invasion (N = 56)
No 9/0 100 0.07
Yes 47/16 66.8 (48.9 – 78.5)
ER expression (N = 61)
Negative 34/16 44.4 (24.1 – 62.9) 0.001
Positive 27/3 92.3 (72.6 – 98.0)
PR expression (N = 61)
Negative 42/16 58.4 (39.9 – 73.0) 0.025
Positive 19/3 88.2 (60.2 – 96.9)
HER2 expression (N = 61)
Negative 39/13 68.5 (49.9 – 81.2) 0.81
Positive 22/6 70.0 (39.1 – 84.3)
Triple-negative status (N = 61)
No 45/9 82.6 (66.6 – 91.4) 0.0001
Yes 16/10 25.7 ( 6.4 – 51.0)
Radiation type (N = 62)
Postoperative 55/17 69.4 (54.0 – 80.5) 0.73
Preoperative 7/2 64.3 (15.2 – 90.2)
BID radiation (N = 48)
No 10/3 80.0 (40.9 – 94.6) 0.21
Yes 38/14 58.0 ( 38.9 – 73.0)
EZH2 (N = 62)
No 17/1 92.8 (59.1 – 98.9) 0.01
Yes 45/18 59.2 (41.5 – 73.1)
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Herein, we report that EZH2 expression correlates with
locoregional recurrence in IBC patients who received ra-
diation. Although EZH2 is associated with local failure
after radiation in univariate analyses, it is not independ-
ently associated with local failure, in part because nearly
all patients with ER-negative disease overexpress EZH2,
making it impossible to separate the influences of EZH2
expression and receptor negativity. When examining theinfluence in non-triple negative cohort, however, EZH2
expression trends to be an independent predictor of locor-
egional recurrence. As such EZH2 ER + patients may be
appropriately included in studies of radiosensitizers for
high risk IBC.
The clinical-pathological features of IBC include en-
richment of factors that have been previously associated
with radioresistant disease, including negative receptor
status and a phenotype enriched for radioresistant breast
Table 3 Multivariate Cox model for LRFS in patients who
received radiation
Hazard ratio (95% CI) P value
Triple negative status 5.64 (2.19 – 14.49) <0.0001
Debeb et al. Journal of Experimental & Clinical Cancer Research 2014, 33:58 Page 6 of 7
http://www.jeccr.com/content/33/1/58CSCs [6,12,13]. IBC is known to be associated with a
high incidence of locoregional recurrence [12,14], and
thus, identification of markers and a greater understand-
ing of the biology of radiation resistance in IBC will be
desirable in order to develop novel radiosensitizers that
could improve local control in IBC patients. The clinical
role of EZH2 in radiation resistance has not been re-
ported before. However, several studies have suggested
the possible involvement of EZH2 in radiation resist-
ance. Recent evidence from Hung’s group suggests that
enhanced expression of EZH2 promotes breast CSC ex-
pansion through impairment of the DNA damage repair
protein Rad51 and the activation of RAF1-ERK-β-ca-
tenin signaling [11]. They showed that EZH2-mediated
downregulation of DNA damage repair leads to accumu-
lation of recurrent RAF1 gene amplification in breast
CSCs, which activates p-ERK-β-catenin signaling to pro-
mote CSC expansion. They further revealed that target-
ing EZH2 downstream activation pathways such as
RAF1-ERK signaling with the MEK inhibitor AZD6244
could prevent breast cancer progression by eliminating
CSCs. They further showed that HIF1α, a known medi-
ator of radioresistance in breast cancer, activates the
EZH2 gene and increases EZH2 expression under hyp-
oxic conditions [11]. Other studies have also supported
the possible role for EZH2 in modulating radiation re-
sponse. Dong et al demonstrated that overexpression of
Bmi-1, another PcG protein similar to EZH2, elicits ra-
dioprotective effects in keratinocytes by mitigating the
genotoxic effects of radiation through epigenetic mecha-
nisms [15]. In another study, pharmacologic inhibition
of EZH2 induced radiation sensitivity in atypical teratoid/
rhabdoid tumors in vitro [16], and silencing EZH2 with
RNAi enhanced radiation sensitivity in lung cancer cells
[17]. Collectively, these data together with our current
findings that EZH2 is associated with local failure in IBC
patients support the hypothesis that EZH2 has a signifi-
cant role in promoting resistance to radiation treatment.
However, it remains unknown which, if any, of the known
mechanisms of EZH2 activity actually modulates resist-
ance to radiation therapy.Table 4 Multivariate Cox model for LRFS in patients who
received radiation but excluding those with triple
negative receptor status
Hazard ratio (95% CI) P value
EZH2 6.5 (0.82 – 52.75) 0.077We and others have provided evidence that breast
CSCs are resistant to radiation through upregulation of
stem cell self renewal pathways including β-catenin and
Notch signaling [3,4] and other studies have shown that
CSCs contribute to radioresistance by preferential acti-
vation of the DNA damage checkpoint response and in-
creased DNA repair capacity and by maintaining low
ROS levels [18,19]. EZH2 has been shown to promote
CSC expansion and maintenance [11,20] and to impair
DNA repair via downregulation of Rad51 [11,21]. These
findings seem paradoxical given that downregulation of
Rad51 is expected to increase radiosensitivity but CSC
expansion has been linked with radiation resistance. Fur-
ther studies are warranted to elucidate this paradox by
examining how EZH2 activates radiation resistance
mechanisms in breast cancer cells.
It is to be noted that the tumors included in this study
comprised tissues from refractory or residual tumors after
neoadjuvant systemic therapy. Previous studies have
shown that neoadjuvant chemotherapy increased the CSC
subpopulation [22] and that EZH2 promotes the expan-
sion of CSCs [11,20]. It is possible then that the expression
of EZH2 described in this cohort is influenced by neoadju-
vant chemotherapy. This should be considered in future
studies.
Conclusion
In conclusion, this retrospective study showed that EZH2
is associated with receptor-negative status and lower
locoregional-recurrence free survival rates in IBC patients.
Additional examination of the mechanism of this clinical
finding and its association with triple negative receptor
status is warranted. These findings indicate that EZH2 ex-
pression status may be used in conjunction with ER + sta-
tus to identify a subset of patients with IBC who recur
locally in spite of radiation and may benefit from enroll-
ment in clinical trials testing radiosensitizers. Given the
high frequency of expression of EZH2 and local recur-
rence in IBC patients, targeting EZH2 may provide a novel
therapeutic strategy to improve local failure of patients
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